Table 1. Characteristics of the study group, subdivided by included and excluded patients.
| Variable | TotalN = 1271 | IncludedN = 1116 | ExcludedN = 155 | P-value 1 |
|---|---|---|---|---|
| Donor characteristics | ||||
| Age (mean years ± SD) | 44 ± 14 | 45 ± 14 | 44 ± 16 | 1 |
| Male N (%) | 645 (51%) | 554 (50%) | 91 (59%) | 0.7 |
| Donor type N (%) | ||||
| Living donor | 282 (22%) | 249 (22%) | 33 (21%) | 1 |
| Deceased donor (DBD + DCD) | 989 (78%) | 867 (78%) | 122 (79%) | |
| Recipient characteristics | ||||
| Age (mean years ± SD) | 48 ± 13 | 48 ± 13 | 48 ± 13 | 1 |
| Male N (%) | 739 (58%) | 655 (59%) | 84 (54%) | 1 |
| Initial immunosuppression N (%) | ||||
| Corticosteroids | 1201 (95%) | 1053 (94%) | 148 (95%) | 1 |
| Calcineurin inhibitor (CsA or TAC) | 1182 (93%) | 1039 (93%) | 143 (92%) | 1 |
| Proliferation inhibitor (MPA or AZA) | 979 (77%) | 863 (77%) | 116 (75%) | 1 |
| mTOR inhibitor | 38 (3%) | 31 (3%) | 7 (5%) | 1 |
| Induction therapy N (%) | ||||
| Anti-thymocyte globulin | 103 (8%) | 90 (8%) | 13 (8%) | 1 |
| Anti-CD3 moab | 19 (2%) | 15 (1%) | 4 (3%) | 1 |
| Interleukin–2 receptor antagonist | 199 (16%) | 171 (15%) | 28 (18%) | 1 |
| First transplant N (%) | 1143 (90%) | 1001 (90%) | 142 (92%) | 1 |
| Transplant characteristics | ||||
| Cold ischemia time (mean hours ± SD) | ||||
| Living donors | 2.7 ± 1.9 | 2.7 ± 2.0 | 2.6 ± 0.7 | 1 |
| Deceased donors | 20.7 ± 6.5 | 20.6 ± 6.4 | 21.6 ± 6.8 | 1 |
| HLA no. of 0 mismatches N (%) 2 | 241 (23%) | 213 (23%) | 28 (22%) | 1 |
DBD = deceased brain death, DCD = deceased cardiac death, SD = standard deviation, CsA = cyclosporine A, TAC = tacrolimus, MPA = mycophenolic acid, AZA = azathioprine, mTOR = mammalian target of rapamycin, moab = monoclonal antibody, HLA = human leukocyte antigen. HLA = Human leukocyte antigen.
1Bonferroni corrected for multiple testing
2Data for N = 221 were missing; N = 195 (20%) in the included patients, N = 26 in the excluded (17%), P = 0.9.